Compare DLNG & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLNG | MXCT |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.8M | 155.8M |
| IPO Year | 2013 | 2021 |
| Metric | DLNG | MXCT |
|---|---|---|
| Price | $3.18 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.11 |
| AVG Volume (30 Days) | 61.2K | ★ 1.5M |
| Earning Date | 11-19-2026 | 11-10-2026 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.10 | $15.53 |
| P/E Ratio | $3.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.25 | $0.64 |
| 52 Week High | $4.45 | $1.81 |
| Indicator | DLNG | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 27.02 | 57.00 |
| Support Level | N/A | $1.02 |
| Resistance Level | $3.96 | $1.54 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 11.96 | 48.67 |
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and is winterized, which enables trade in subzero and ice bound conditions.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.